ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Antibodies"

  • Abstract Number: 7 • 2013 ACR/ARHP Annual Meeting

    Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)

    Savino Sciascia1, Mª Jose Cuadrado2, Giovanni Sanna3, Veronica Murru4, Dario Roccatello1, Oier Ateka5, Munther A. Khamashta6 and Maria Laura Bertolaccini4, 1Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 2Lupus Research Unit, The Rayne Institute, London, United Kingdom, 3Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, 4Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 5Lupus Unit, London, United Kingdom, 6Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom

    Prospective Validation of the Global Antiphospholipid Syndrome Score (GAPSS) Background/Purpose: Backgrounds: This study was performed to prospectively and independently validate the GAPSS (1) (Global APS…
  • Abstract Number: 286 • 2012 ACR/ARHP Annual Meeting

    The Association of N-Methyl-D-Aspartate Receptor Antibodies and Neurocognitive Dysfunction in Pediatric Lupus Patients and in the Offspring of Adult Patients with Lupus

    Natasha M. Ruth1, Mary C. Kral2, Stephanie Slan3, Tamara K. Nowling4, Murray H. Passo1 and Gary S. Gilkeson3, 1Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, 2Genetics and Developmental Pediatrics, MUSC, Charleston, SC, 3Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 4Medical University of South Carolina, Charleston, SC

    Background/Purpose: Approximately 1/5 of all systemic lupus erythematosus (SLE) starts in childhood and central nervous system (CNS) dysfunction is more common in childhood-onset SLE.  CNS…
  • Abstract Number: 2618 • 2012 ACR/ARHP Annual Meeting

    Lupus Disease Activity Severely Impairs Pandemic Influenza A/H1N1 Vaccine Immune Response in Patients without Therapy

    Eduardo F. Borba1, Sandra G. Pasoto1, Ana L. Calich1, Ricardo Fuller1, Vilma S.T. Viana1, Margareth Vendramini1, Joao Miraglia2, Maria A. Ishida3 and Eloisa Bonfa4, 1Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, 2Instituto Butantan, Fundação Butantan, São Paulo, Brazil, 3Instituto Adolfo Lutz, São Paulo, Brazil, 4Rheumatology Division, University of São Paulo, Sao Paulo, Brazil

    Background/Purpose: To determine the influence of disease activity without the effect of drugs in pandemic 2009 influenza A (H1N1) vaccine immune response in untreated systemic…
  • Abstract Number: 216 • 2012 ACR/ARHP Annual Meeting

    Clinical and Serological Associations of Malignancy in Adult Patients with Polymyositis and Dermatomyositis

    Yuji Hosono1, Ran Nakashima1, Yoshitaka Imura2, Naoichiro Yukawa3, Hajime Yoshifuji1, Motomu Hashimoto4, Koichiro Ohmura5, Takao Fujii6 and Tsuneyo Mimori1, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 3Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 4The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Rheumatology & Clin Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 6Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan

    Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are systemic connective tissue disorders, which are often associated with internal malignancy. Several studies have reported the association between…
  • Abstract Number: 2659 • 2012 ACR/ARHP Annual Meeting

    An Expanded Repertoire of Anti-Citrullinated Peptide Antibodies Is Associated with Interstitial Lung Disease in Rheumatoid Arthritis

    Jon T. Giles1, Sonye Danoff2, Jeremy Sokolove3, Robert Winchester4, Dimitrios A. Pappas5, Catriona Cramb6, Geoffrey Connors7, Stanley S. Siegelman8, William H. Robinson9 and Joan M. Bathon5, 1Medicine, Columbia University, New York, NY, 2Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, 3Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 4Dept of Medicine & Pathology, Columbia University, New York, NY, 5Columbia University, New York, NY, 6VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, 7Division of Pulmonary and Critical Care Medicine, Yale University, New Haven, CT, 8Department of Radiology, Johns Hopkins University, Baltimore, MD, 9Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: Interstitial lung disease (ILD) is an outcome with high morbidity and mortality in rheumatoid arthritis (RA).  Citrullinated proteins are observed in these lung tissues;…
  • Abstract Number: 349 • 2012 ACR/ARHP Annual Meeting

    Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab

    Clifton O. Bingham III1, Warren C. Rizzo2, Micki Klearman3, Azra Hassanali4, Ruchi Upmanyu5 and Alan J. Kivitz6, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Advanced Arthritis Care & Research, Scottsdale, AZ, 3Genentech Inc, South San Francisco, CA, 4Genentech Inc, San Francisco, CA, 5Roche, Welwyn Garden City, United Kingdom, 6Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose: Tocilizumab (TCZ) is an IL-6–receptor inhibitor for treatment of rheumatoid arthritis (RA) patients (pts). Because TCZ may impact how IL-6 modulates T-cell activation and…
  • Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting

    Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients

    Mathieu Verdet1, Clément Guillou2, Marie-Laure Potier2, Martine Hiron2, Fabienne Jouen3, Olivier Boyer4, Thierry Lequerré5 and Olivier Vittecoq6, 1Rheumatology, Rouen University Hospital, Bois Guillaume, France, 2Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 3Immunology, Rouen University Hospital, Rouen Cedex, France, 4Immunology, INSERM U905, University of Rouen, Rouen, France, 5Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 6Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France

    Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…
  • Abstract Number: 665 • 2012 ACR/ARHP Annual Meeting

    Cytokines and Their Relation to Autoantibodies Before Disease Onset in Systemic Lupus Erythematosus

    Catharina Eriksson1 and Solbritt Rantapää Dahlqvist2, 1Department of Clinical Immunology/clinical microbiology, Umeå, Sweden, 2Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden

    Background/Purpose: Cytokines and autoantibodies are involved in the pathogenesis of systemic lupus erythematosus (SLE). The presence of autoantibodies preceding disease onset by years has been…
  • Abstract Number: 683 • 2012 ACR/ARHP Annual Meeting

    Prevalence of Inhibitory or Non-Inhibitory Autoantibodies to Angiotensin Converting Enzyme 2 (ACE2) in Patients with Systemic Lupus Erythematosus

    Yuko Takahashi1, Shiori Haga2, Yukihito Ishizaka2 and Akio Mimori3, 1Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan, 2Department of Intractable Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan, 3Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan

    Background/Purpose: We previously reported that inhibitory autoantibodies to angiotensin converting enzyme 2 (ACE2) predisposed individuals to connective tissue diseases (i.e., scleroderma or systemic lupus erythematosus…
  • Abstract Number: 836 • 2012 ACR/ARHP Annual Meeting

    Clinical Responses and Patient Reported Outcomes to NNC0109-0012 (anti-IL-20 mAb) in Rheumatoid  Arthritis (RA) Patients Following 12-Weeks Dosing and 13 Weeks Follow up: Results From a Phase 2a Trial

    Ladislav ŠEnolt1, Marie Göthberg2, Xavier Valencia3 and Eva Dokoupilova4, 1Institute of Rheumatology, Prague, Czech Republic, 2Biostatistics, Novo Nordisk, A/S, Soeborg, Denmark, 3Clinical Medical and Regulatory Affairs, Novo Nordisk, Inc., Princeton, NJ, 4Medical Plus s.r.o, Uherske Hradiste, Czech Republic

    Background/Purpose: NNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to and neutralizes the activity of IL-20. Data from a phase 1…
  • Abstract Number: 835 • 2012 ACR/ARHP Annual Meeting

    Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered Anti-CD20 Antibody, Result in Rapid and Sustained Depletion of Circulating B-Cells in Rheumatoid Arthritis Patients

    Adrienne O'Reilly, Tracy Davis and Vinay Jain, Mentrik Biotech, Dallas, TX

     Background/Purpose:   B-cell depletion provides therapeutic benefits for patients with rheumatoid arthritis (RA). Ocaratuzumab, previously known as AME-133v, is a Fc- and Fab-engineered, humanized, anti-CD20…
  • Abstract Number: 948 • 2012 ACR/ARHP Annual Meeting

    Antibody-Based Prediction Rules for Connective Tissue Disease: Analysis of 12,555 Patients with Antinuclear Antibody Testing

    Ryo Rokutanda1, Mitsumasa Kishimoto1, Yasuharu Tokuda2, Ken-ichi Yamaguchi1, Hisanori Shimizu1, Yasuhiro Suyama1, Yuri Ohara1, Yoichiro Haji1, Chisun Min1, Akira Takeda1, Yukio Matsui3 and Masato Okada1, 1Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, 2Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan, 3Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan

    Background/Purpose: Antinuclear antibody (ANA) is widely used as a screening test for connective tissue diseases (CTDs). The sensitivity of this test is high in 3…
  • Abstract Number: 1178 • 2012 ACR/ARHP Annual Meeting

    IL-6 and IL-21 in Rheumatoid Arthritis

    Gustavo Carbone1, Augusta Wilson1, Sean Diehl2, Janice Bunn3, Sheldon Cooper4 and Mercedes Rincon5, 1Rheum & Clinical Imm Unit, University of Vermont College of Medicine, Burlington, VT, 2Immunobiology, University of Vermont College of Medicine, 3Mathematics and Statistics, University of Vermont, Burlington, VT, 4Rheum & Clinical Imm Unit, Univ Vermont College of Med, Burlington, VT, 5Immunobiology, University of Vermont College of Medicine, Burlington, VT

    Background/Purpose: Interleukin-6 (IL-6) levels are known to be increased in patients with rheumatoid arthritis (RA). Tocilizumab, a monoclonal antibody to the IL-6 receptor (IL-6R), reduces…
  • Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting

    Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab

    Chad Pool1, Gopi Shankar2, Allen Schantz2, George Gunn2, Rebecca Bolce3, Marjatta Leirisalo-Repo4, Jim Wang1, John A. Goldman5, Raphael J. DeHoratius6, Roy Fleischmann7 and Dennis Decktor6, 1Janssen Services, LLC, Horsham, PA, 2Janssen R&D, LLC, PA, 3Crescendo Bioscience Inc., South San Francisco, CA, 4Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, 5Medical Quarters #293, Atlanta, GA, 6Medical Affairs, Janssen Services, LLC, Horsham, PA, 7Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…
  • Abstract Number: 1491 • 2012 ACR/ARHP Annual Meeting

    Systemic Sclerosis – Effects of Agonistic Autoantibodies Directed Against the Angiotensin Receptor Type 1 and the Endothelin Receptor Type A On Effector Cells

    Jeannine Guenther1, Angela Kill2, Mike O. Becker3 and Gabriela Riemekasten4, 1Rheumatology/Clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, Berlin, Germany, 2Rheumatology and clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, 3Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, 4Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany

    Background/Purpose: Autoimmunity, vasculopathy and fibrosis are features of systemic sclerosis (SSc). The functional link between these three pathophysiological components is still missing. Research suggests an…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies